Liu Yanmei, Dalal Koustuv
MPH Student, Karolinska Institutet, Sweden.
Int J Prev Med. 2011 Apr;2(2):64-72.
Myocardial infarction (MI) is a leading cause of death in both the industrialized and developing countries globally. The economic evaluation of MI is undertaken to rationale the allocation of scarce healthcare resource. The objective is to review cost-effectiveness analysis of MI with medications.
WE SEARCHED PUBMED USING THE KEY WORDS: "cost effectiveness analysis"and "myocardial infarction" After applying the selection criteria, eight articles were selected for the present study.
Out of eight articles, five had studied thrombolytic agents. All of these papers clearly explain the costs and benefits of different drugs for MI. ICER was assessed in six out of the eight articles to compare the costs and health effects between alternative medications. ICER was expressed in different effect units.
This study found that various medications including thrombolytic agents, ACEI and heparin are administered to treat MI in many countries. It is also found that five of eight studies focus on thrombolytic therapies. It implies that thrombolytic is generally very cost effective for MI to the whole society.
心肌梗死（MI）是全球工业化国家和发展中国家的主要死因。对心肌梗死进行经济评估是为了合理分配稀缺的医疗资源。目的是回顾心肌梗死药物治疗的成本效益分析。
我们在PubMed上使用关键词“成本效益分析”和“心肌梗死”进行搜索。应用选择标准后，为本研究选择了8篇文章。
在8篇文章中，有5篇研究了溶栓药物。所有这些论文都清楚地解释了不同药物治疗心肌梗死的成本和效益。8篇文章中有6篇评估了增量成本效果比（ICER），以比较替代药物之间的成本和健康效果。ICER以不同的效果单位表示。
本研究发现，许多国家使用包括溶栓药物、血管紧张素转换酶抑制剂（ACEI）和肝素在内的各种药物治疗心肌梗死。还发现8项研究中有5项侧重于溶栓治疗。这意味着溶栓治疗对整个社会的心肌梗死患者通常具有很高的成本效益。
